Aesthetic manufacturer Croma-Pharma has announced the national approval of its new botulinum toxin in the UK.
According to the company, the toxin, Letybo, has been approved for the treatment of glabellar lines. The neurotoxin aims to provide practitioners and patients with efficacy and tolerability. The new toxin received a 94% response rate four weeks after injection.
Managing director Andreas Prinz, commented, “We are proud to be the first Austrian family-owned pharmaceutical company launching its own neurotoxin to the aesthetic market. In the upcoming weeks and months, we expect national approvals for Letybo in additional European countries. With this completed portfolio, we will now be able to meet our customers’ needs even better.”
